Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Feb 1;29(2):398-404.
doi: 10.1093/annonc/mdx716.

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial

L Ek  1 , E Gezelius  2 , B Bergman  3 , P O Bendahl  4 , H Anderson  5 , J Sundberg  6 , M Wallberg  1 , U Falkmer  7 , S Verma  8 , M Belting  9 ; Swedish Lung Cancer Study Group (SLUSG)
Affiliations
Clinical Trial

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial

L Ek et al. Ann Oncol. .

Abstract

Background: Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a major cause of morbidity and mortality in cancer. Coagulation inhibition with low-molecular-weight heparin (LMWH) may improve survival specifically in small-cell lung cancer (SCLC) patients by preventing VTE and tumor progression; however, randomized trials with well-defined patient populations are needed to obtain conclusive data. The aim of RASTEN was to investigate the survival effect of LMWH enoxaparin in a homogenous population of SCLC patients.

Patients and methods: We carried out a randomized, multicenter, open-label trial to investigate the addition of enoxaparin at a supraprophylactic dose (1 mg/kg) to standard treatment in patients with newly diagnosed SCLC. The primary outcome was overall survival (OS), and secondary outcomes were progression-free survival (PFS), incidence of VTE and hemorrhagic events.

Results: In RASTEN, 390 patients were randomized over an 8-year period (2008-2016), of whom 186 and 191 were included in the final analysis in the LMWH and control arm, respectively. We found no evidence of a difference in OS or PFS by the addition of enoxaparin [hazard ratio (HR), 1.11; 95% confidence interval (CI) 0.89-1.38; P = 0.36 and HR, 1.18; 95% CI 0.95-1.46; P = 0.14, respectively]. Subgroup analysis of patients with limited and extensive disease did not show reduced mortality by enoxaparin. The incidence of VTE was significantly reduced in the LMWH arm (HR, 0.31; 95% CI 0.11-0.84; P = 0.02). Hemorrhagic events were more frequent in the LMWH-treated group but fatal bleedings occurred in both arms.

Conclusion: LMWH enoxaparin in addition to standard therapy did not improve OS in SCLC patients despite being administered at a supraprophylactic dose and despite resulting in a significant reduction in VTE incidence. Addition of LMWH cannot be generally recommended in the management of SCLC patients, and predictive biomarkers of VTE and LMWH-associated bleeding in cancer patients are warranted.

Trial registration: ClinicalTrials.gov NCT00717938.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram of the RASTEN study population.
Figure 2.
Figure 2.
Kaplan–Meier curve of overall survival by treatment arm.
Figure 3.
Figure 3.
Kaplan–Meier curves of overall survival by disease extent according to treatment arm.
Figure 4.
Figure 4.
Cumulative incidence of first venous thromboembolism (VTE).
See this image and copyright information in PMC

References

    1. Ervik M, Lam F, Ferlay J. et al. Cancer Today: Cancer fact sheets: Lung Cancer, 05/2016 update; http://gco.iarc.fr/today.
    1. Walters S, Maringe C, Coleman MP. et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013; 68(6): 551–564. - PubMed
    1. Blom JW, Doggen CJ, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293(6): 715–722. - PubMed
    1. Rak J, Yu JL, Luyendyk J. et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66(22): 10643–10646. - PubMed
    1. Kasthuri RS, Taubman MB, Mackman N.. Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834–4838. - PMC - PubMed

Publication types

MeSH terms

Associated data